INC Research Drives Deeper Site Connections Through Strengthened Study Start-up Effort

Carol Aliyar named Senior Vice President, Study Start-Up to lead Company's strategic site initiatives and focus on enhancing the start-up experience for customers worldwide

Raleigh, N.C.--INC Research, a leading, global Phase I to IV clinical research organization (CRO), today announced the promotion of Carol Aliyar to Senior Vice President, Study Start-Up. Ms. Aliyar will be responsible for leading the Company's global site engagement and study start-up efforts, including study start-up operations, site identification, site start-up and activation, ethics and regulatory submissions/approval and patient recruitment. She brings more than two decades of clinical operations experience to her new role, including broad therapeutic expertise and experience in leading large-scale global clinical development programs. As Senior Vice President, Study Start-Up, Ms. Aliyar will focus on fostering strong site relationships to optimize timelines and deliver rapid study start-up for global clinical trials, establishing the foundation for successful collaboration across the duration of a study.

"Developing long-lasting relationships with clinical research sites is critically important to our ability to deliver best-in-class clinical development solutions for our customers," said Alistair Macdonald, Chief Operating Officer, INC Research. "Study start-up is an essential phase in this process because it serves as the initial interaction point with sites and customers and defines the relationship for the duration of the trial. The appointment of an experienced and dynamic leader for this important function demonstrates our commitment to delivery of innovative and effective site selection and start-up strategies that provide valuable time-saving results for our customers."

Prior to joining INC in September 2012 to lead Site Start-Up and Regulatory for Europe, Ms. Aliyar held senior management positions at global CROs and at an international biopharmaceutical company. Under her direction, INC Research's team will deliver a personalized and integrated approach that optimizes the start-up experience through strengthened collaboration and improved information exchange with our site partners.

"With 48 percent of studies failing to meet enrollment targets and more than 11 percent unable to recruit a single patient, the industry faces many challenges today in trial execution," said Ms. Aliyar. "My team is committed to establishing partnership principles with sites to ensure they are motivated and well supported to deliver on enrollment targets, which are vital to a study's success. The depth of this support will showcase the strength, reliability and consistency of our proven process."

About INC Research
INC Research is a leading global contract research organization (CRO) providing the full range ofPhase I to Phase IV clinical development services for the world's biopharmaceutical and medical device industry. As a therapeutically focused CRO, with a Trusted Process® delivery methodology, developing the medicines people need is something we take personally. Leveraging the breadth of our service offerings and the depth of our therapeutic expertise across multiple patient populations,INC Research connects customers, clinical research sites and patients to accelerate the delivery of new medicines to market to improve world health. We were ranked "Top CRO to Work With" by sites worldwide in the 2013 CenterWatch Global Investigative Site Relationship Survey. INC Research is headquartered in Raleigh, NC, with operations across six continents and experience spanning more than 100 countries. For more information, please visit www.incresearch.com and connect with us on LinkedIn and Twitter @inc_research

Contact: Lori Dorer, Media +1 (513) 345-1685

Suggested Articles

Genesis Drug Discovery & Development has bought up New England Discovery Partners as it looks to boost its synthetic and medicinal chemistry.

Sanofi plans to incorporate its real-world data platform with Aetion’s analytics system to better develop studies for regulatory decision-making.

Major CRO player Pharmaceutical Product Development is set to go back on the public markets after announcing its IPO plans.